US OptionsDetailed Quotes

AZN250404P80000

Watchlist

4.85
0.000.00%

15min DelayClose Apr 4 16:00 ET

0.00High0.00Low

AstraZeneca Stock Discussion

Movers and Shakers

Apr 3 20:16

Columns Today's Pre-Market Movers and Top Ratings | TSLA, AAPL, AZN and More

Morning Movers
Gapping Up
$Diageo (DEO.US)$ shares rose 4.6% in pre-market trading, as U.S. tariffs avoided the worst-case scenario for spirits. Goodbody noted no new duties on Canadian and Mexican imports, while Jefferies highlighted the avoidance of a potential 200% tariff on EU alcohol, benefiting European distillers.
Pharmaceutical shares are up in pre-market trading as drug imports could be exempt from the new 'reciprocal ta...

Trump's tariff storm sweeps the market, how to balance offense and defense?

Teddy123

Mar 31 19:22

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

$AstraZeneca (AZN.US)$
Breakthrough: First-Ever FDA-Approved Immunotherapy Shows 32% Better Outcomes in Bladder Cancer

Teddy123

Mar 26 12:33

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

$AstraZeneca (AZN.US)$
Major Breakthrough: AstraZeneca's TAGRISSO Extends Lung Cancer Survival to Nearly 5 Years

Teddy123

Feb 28 21:12

$AstraZeneca (AZN.US)$
ENHERTU Shows 38% Reduced Death Risk in Breast Cancer - EU Approval Now One Step Closer

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Teddy123

Feb 26 20:14

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor

$AstraZeneca (AZN.US)$
Can This Breakthrough Breast Cancer Drug Transform AstraZeneca's Oncology Portfolio?

Ryand83

Feb 25 08:28

$LumiraDx (LMDXF.US)$ if we started bringing awareness to X FB and other social media platforms we could probably win this fight. I stayed in Lumiradx because I figured if $AstraZeneca (AZN.US)$ had scooped it up we would have been jipped. $ROCHE HOLDING AG (RHHBY.US)$ seemed like a better fit as they have a plethora of innovative solutions to revitalize companies. 350m seems like an $Abbott Laboratories (ABT.US)$ or $Johnson & Johnson (JNJ.US)$ move to me and I don't buy it. Not from Roche.